Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Bayer brands
Factor VIII (medication)
Другие языки:

Factor VIII (medication)

Подписчиков: 0, рейтинг: 0
Factor VIII
Fviii 2R7E.png
A depiction of factor VIII
Clinical data
Trade names Aafact, Kovaltry, others
Other names octocog alfa
AHFS/Drugs.com Monograph
License data
Routes of
administration		 Intravenous (IV)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
ChemSpider
  • none

Factor VIII is a medication used to treat and prevent bleeding in people with hemophilia A and other causes of low factor VIII. Certain preparations may also be used in those with von Willebrand's disease. It is given by slow injection into a vein.

Side effects include skin flushing, shortness of breath, fever, and red blood cell breakdown.Allergic reactions including anaphylaxis may occur. It is unclear if use during pregnancy is safe for the fetus. A purified factor VIII concentrate is made from human blood plasma. A recombinant version is also available. People may develop antibodies to factor VIII such that this medication becomes less effective.

Factor VIII was first identified in the 1940s and became available as a medication in the 1960s. Recombinant factor VIII was first made in 1984 and approved for medical use in the United States in 1992. It is on the World Health Organization's List of Essential Medicines.

Available forms

Factor VIII is delivered by intravenous infusion.

History

This transfer of a plasma byproduct into the blood stream of a hemophiliac often led to the transmission of diseases such as HIV and hepatitis before purification methods were improved. In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy.

Society and culture

Economics

The cost of Factor VIII and similar clotting factors has been described as "highly expensive". The cost of the clotting factors is 80% of all medical costs for people with hemophilia. They are so expensive that gene therapy for haemophilia might be less expensive, especially for people with severe hemophilia.

See also

External links


Новое сообщение